NAMSA Acquires Clinlogix Clinical Research Organization

August 5, 2021—NAMSA announced its acquisition of Clinlogix, a global clinical research organization. NAMSA is a global, full-continuum contract research organization focused on medical devices. It was founded in 1967 and headquartered in Toledo, Ohio. The price and terms of the transaction were not disclosed.

According to the announcement, Clinlogix, founded in 1999 and based in Philadelphia, Pennsylvania, provides comprehensive clinical research services for novel and emerging technologies to the medical device industry. Clinlogix supports more than 500 trials across 3,500 sites worldwide in cardiovascular, neurology, nephrology, urology, oncology, and venous/wound care clinical research.

NAMSA provides testing services to sponsors in addition to quality, reimbursement, clinical research, and regulatory solutions. The contract research organization’s end-to-end development services help sponsors successfully address varying global regulatory requirements, including recently expanded criteria for medical device and in vitro diagnostic research and conduct, stated NAMSA

In early 2021, NAMSA announced the acquisition of the contract research organization Syntactx, as well as American Preclinical Services.